|
Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer). |
|
|
Travel, Accommodations, Expenses - PharmaMar; Tesaro |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - PharmaMar; Roche Belgium; Tesaro |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche; Tesaro |
Speakers' Bureau - AstraZeneca; PharmaMar |
Research Funding - Merck; PharmaMar |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Pfizer; PharmaMar; Roche; tesaro |
Research Funding - AstraZeneca (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |